Leptin therapy in insulin-deficient type I diabetes

May Yun Wang, Lijun Chen, Gregory O. Clark, Young Lee, Robert D. Stevens, Olga R. Ilkayeva, Brett R. Wenner, James R. Bain, Maureen J. Charron, Christopher B. Newgard, Roger H. Unger

Research output: Contribution to journalArticlepeer-review

263 Scopus citations


In nonobese diabetic mice with uncontrolled type 1 diabetes, leptin therapy alone or combined with low-dose insulin reverses the catabolic state through suppression of hyperglucagonemia. Additionally, it mimics the anabolic actions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability. We showthat leptin therapy, like insulin, normalizes the levels of a wide array of hepatic intermediary metabolites in multiple chemical classes, including acylcarnitines, organic acids (tricarboxylic acid cycle intermediates), amino acids, and acyl CoAs. In contrast to insulin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids. The results imply that leptin administration may have multiple short- and long-term advantages over insulin monotherapy for type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)4813-4819
Number of pages7
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number11
StatePublished - Mar 16 2010


  • Cholesterol regulation
  • Glucagon suppression
  • Glucose regulation
  • Lipid-lowering
  • Metabolomics

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Leptin therapy in insulin-deficient type I diabetes'. Together they form a unique fingerprint.

Cite this